64 completed, 29 unknown, 7 withdrawn, 6 terminated. 24 Not applicable, 22 Phase 2, 15 Phase 3, 9 Phase 1, 3 Early Phase 1.
Follow COVID 19: new trials by email Literature Review of COVID 19 trials Research Report on COVID 19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study Pfizer-BioNTech mRNA COVID-19 vaccine, Novavax recombinant protein vaccine - COVID -19, COVID - 19 | Phase 4 | Recruiting | Henry M. Jackson Foundation for the Advancement of Military Medicine | 54 | 2025-11-12 | 2026-10-28 |
| Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19 Functional and cognitive rehabilitation strategy, Evidence-Based Informational Support - Long COVID-19 Syndrome, COVID 19 | Not applicable | Recruiting | Fundación Cardioinfantil Instituto de Cardiología | 374 | 2025-10-30 | 2026-04-13 |
| Community-based Behavioral Intervention to Increase Vaccination Using MOST Health education on COVID and flu vaccination, Nurse-led shared decision-making, Text messages - COVID 19, Influenza | Phase 2 | Withdrawn | New York University | 2025-04-01 | 2025-04-29 | |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function ALG-097558 - COVID 19 | Phase 1 | Completed | Aligos Therapeutics | 12 | 2025-02-20 | 2026-08-25 |
| Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza Nitazoxanide 600Mg Oral Tablet / placebo oral tablet - Covid 19, Influenza | Phase 3 | Not yet recruiting | Azidus Brasil | 340 | 2025-02-01 | 2025-02-10 |
| COVID-19 Booster and IIV Schedule in Immunocompromised Hosts Inactivated influenza vaccine (IIV) at baseline, COVID-19 Vaccines at a 3-month interval, Inactivated influenza vaccine at Month 1 - COVID 19, Influenza | Phase 2 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 660 | 2024-11-20 | 2026-10-26 |
| A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients LIAISON NES FLU A/B, RSV & COVID-19 - Influenza a, Influenza B | Not applicable | Recruiting | DiaSorin Molecular LLC | 1000 | 2024-09-30 | 2024-11-04 |
| Singapore SARS-CoV-2 Human Challenge Study GMP-produced SARS-CoV-2 Delta strain - COVID 19 | Not applicable | Active not recruiting | Tan Tock Seng Hospital | 20 | 2024-08-27 | 2026-01-12 |
| Pandemic-Proofing Simulation-based Education VR Headset, Traditional Theatre-based simulation - COVID 19 | Not applicable | Unknown | Ottawa Hospital Research Institute | 45 | 2023-07-01 | 2023-07-05 |
| Colostrum From MERS-CoV Seropositive Camels for SARS-CoV-2 Infection - a Placebo-controlled Randomized Trial. Colostrum Nasal Spray, Water for injection - COVID 19 | Phase 1 / Phase 2 | Completed | Hadassah Medical Organization | 43 | 2023-05-01 | 2025-03-04 |
| Thromboembolic Complications in Mild Covid-19 Cases COVID 19, Thromboembolic and Bleeding Complications | Completed | Marmara University Pendik Training and Research Hospital | 961 | 2022-01-01 | 2024-11-19 | |
| GlowTest COVID-19 Antigen Home Test Kit QRI Use Study GlowTest COVID-19 Antigen Home Test - Covid 19 | Not applicable | Completed | Arion Bio | 33 | 2021-12-06 | 2021-12-20 |
| Eccentric Cycling Vs. Standard Rehabilitation for Post-ICU Recovery in COVID-19 Survivors Eccentric cycling training, Standar Rehabilitation - COVID 19 | Not applicable | Completed | Universidad Nacional Andres Bello | 20 | 2021-10-30 | 2025-03-26 |
| Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO) Covid 19 | Unknown | Methodist Health System | 400 | 2021-10-19 | 2022-10-26 | |
| Audiological Assessment of Recovered Covid 19 Subjects. Audiological assessment - Covid 19 | Unknown | Assiut University | 70 | 2021-10-01 | 2021-09-24 | |
| Efficacy and Immunomodulator Impact of Herbal Combination on COVID-19 Patients Recovery Placebo, herbal compound - COVID 19 | Not applicable | Completed | Universitas Indonesia | 66 | 2021-08-27 | 2024-10-15 |
| Cognitive and Psychological Disorders After Severe COVID-19 Infection Cognitive assessment, Imaging, Routine care - COVID 19 | Not applicable | Completed | Central Hospital, Nancy, France | 76 | 2021-08-23 | 2024-02-09 |
| B Cell Responses in COVID-19 COVID 19 | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 4 | 2021-07-07 | 2025-04-30 | |
| Feasibility of a Tele-game-based Exercise (Tele-exergame) Program to Prevent Deconditioning in Hospitalized COVID-19 Patients Tele-exergaming Tablet - COVID 19, Rehabilitation | Not applicable | Completed | VA Office of Research and Development | 54 | 2021-07-05 | 2026-08-05 |
| Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects HLX71, Placebo - COVID 19 | Phase 1 | Completed | Hengenix Biotech Inc | 32 | 2021-04-08 | 2022-04-01 |
Showing 20 of 117. Sign in to see all of them.
COVID-19 (117) · Coronavirus Infections (7) · Influenza, Human (5) · Depression (4) · Pneumonia (3) · Respiratory Insufficiency (3) · Virus Diseases (3) · Cytokine Release Syndrome (2) · Diabetes Mellitus (2) · Inflammation (2) · Respiratory Distress Syndrome (2) · Social Isolation (2) · Stress, Psychological (2) · Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1)
Infections (117) · Nidovirales Infections (117) · Pneumonia, Viral (117) · RNA Virus Infections (117) · Respiratory Tract Infections (117) · Coronaviridae Infections (116) · Lung Diseases (116) · Respiratory Tract Diseases (116) · Pneumonia (114) · Virus Diseases (114) · Coronavirus Infections (110) · Pathological Conditions, Signs and Symptoms (8) · Pathologic Processes (7) · Behavior (6) · Behavioral Symptoms (5)
Hydroxychloroquine (6) · Azithromycin (2) · Blood Specimen Collection (2) · COVID-19 Serotherapy (2) · Injections (2) · Oseltamivir (2) · Restraint, Physical (2) · Standard of Care (2) · Surveys and Questionnaires (2) · mavrilimumab (2) · Almitrine (1) · Autopsy (1) · Biosensing Techniques (1) · Bromhexine (1) · COVID-19 Nucleic Acid Testing (1)
University Hospital, Montpellier (10) · Washington University School of Medicine (3) · Alexandria University (2) · Assistance Publique - Hôpitaux de Paris (2) · Central Hospital, Nancy, France (2) · Centre Hospitalier Universitaire de Nice (2) · Damanhour University (2) · Hengenix Biotech Inc (2) · Lomonosov Moscow State University Medical Research and Educational Center (2) · McGill University Health Centre/Research Institute of the McGill University Health Centre (2) · Vinmec Research Institute of Stem Cell and Gene Technology (2) · Aarogyam UK (1) · Abderrahmane Mami Hospital (1) · Aga Khan University (1) · Al-Neelain University (1)
France (22) · United States (22) · Egypt (6) · Italy (6) · Turkey (Türkiye) (5) · Belgium (3) · Canada (3) · Israel (3) · Pakistan (3) · Russia (3) · United Kingdom (3) · India (2) · Indonesia (2) · Mexico (2) · Norway (2)
Emilie Olie, MD PhD (3) · Ayman I Baess, MD (2) · Mohamed Mamdouh Elsayed, MD (2) · Nermine H Zakaria, MD (2) · Ahmad Faried, Prof. MD (1) · Akram M Fayed, MD (1) · Andreas Barratt-Due, MD, PhD (1) · Andrey Pulin, MD, PhD (1) · Anne Drewry, MD (1) · Anne Margarita Dyrhol Riise, MD, Professor (1) · Arash Shirvani, MD, PhD (1) · Arief Nurudin, MD PhD (1) · Aristomenis Extradaktylos, Prof. MD (1)
PMID 33754144, PMID 34473343, PMID 25793605, PMID 29543693, PMID 29859173, PMID 29879021, PMID 31168572, PMID 31756987, PMID 32053470, PMID 32085846, PMID 32162702, PMID 32167524, PMID 32214286, PMID 32252338, PMID 32265310, PMID 32281062, PMID 32602006, PMID 32692012, PMID 32756149, PMID 32771032, PMID 32891160, PMID 33080051, PMID 33165755, PMID 33180097, PMID 33201181, PMID 33222617, PMID 33240091, PMID 33259540, PMID 33329400, PMID 33346365, PMID 33516247, PMID 33560386, PMID 33627230, PMID 33646505, PMID 33715099, PMID 33727235, PMID 33741308, PMID 33742434, PMID 33750252, PMID 33757717, PMID 33819166, PMID 33825846, PMID 33845032, PMID 33996529, PMID 34129486, PMID 34154809, PMID 34235578, PMID 34251903, PMID 34308137, PMID 34350582
2023 (1), 2025 (1)